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Abstract
Background: The independent oversight of clinical trials, which is recommended by the Medical Research Council
(MRC) Guidelines for Good Clinical Practice, is typically provided by an independent advisory Data Monitoring
Committee (DMC) and an independent executive committee, to whom the DMC makes recommendations. The
detailed roles and function of this executive committee, known as the Trial Steering Committee (TSC), have not
previously been studied or reviewed since those originally proposed by the MRC in 1998.
Methods: An expert panel (n = 7) was convened comprising statisticians, clinicians and trial methodologists with
prior TSC experience. Twelve questions about the role and responsibilities of the TSC were discussed by the panel
at two full-day meetings. Each meeting was transcribed in full and the discussions were summarised.
Results: The expert panel reached agreement on the role of the TSC, to which it was accountable, the membership,
the definition of independence, and the experience and training needed. The management of ethical issues, difficult/
complex situations and issues the TSC should not ask the DMC to make recommendations on were more difficult to
discuss without specific examples, but support existed for further work to help share issues and to provide appropriate
training for TSC members. Additional topics discussed, which had not been identified by previous work relating to the
DMCs but were pertinent to the role of the TSC, included the following: review of data sharing requests, indemnity,
lifespan of the TSC, general TSC administration, and the roles of both the Funder and the Sponsor.
Conclusions: This paper presents recommendations that will contribute to the revision and update of the MRC TSC
terms of reference. Uncertainty remains in some areas due to the absence of real-life examples; future guidance on
these issues would benefit from a repository of case studies. Notably, the role of a patient and public involvement (PPI)
contributor was not discussed, and further work is warranted to explore the role of a PPI contributor in independent
trial oversight.
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Background
Independent oversight committees are recommended in
the management of clinical trials. The Medical Research
Council (MRC) Guidelines for Good Clinical Practice
(1998) defines a three-committee oversight structure that
has been widely adopted in the UK: the Trial Management
Group (TMG), the Data Monitoring Committee (DMC)
and the executive Trial Steering Committee [1]. The TMG
is responsible for the day-to-day delivery and conduct of
the trial; the DMC role is to review safety and efficacy data
and make recommendations to an executive group; and
the TSC is the executive decision-making group that
considers the recommendations from the DMC. Members
of the TMG are not independent from the trial; all mem-
bers of the DMC are independent; and the TSC has both
independent members and members who are also part of
the TMG.
Extensive work as part of the DAMOCLES study [2]
has been done to establish why and when DMCs are
needed; their roles, responsibilities and structure; their
organisation; and their decision-making and reporting
arrangements. The DAMOCLES study concluded that
the role of the DMC, as indicated within their Charter, is
not to make decisions about the trial but rather to make
recommendations to an appropriate executive committee
[3]. The appropriate executive committee that considers
these recommendations is the Trial Steering Committee
(TSC), yet, to date, no such in-depth project establishing
the role, responsibilities, and organisation of this commit-
tee has been conducted. The remit, objectives and func-
tionality of the TSC is usually described and documented
in the TSC terms of reference. The MRC TSC terms of
reference, an appendix of the 1998 MRC guidelines for
Good Clinical Practice [1], describe the role of the TSC as
providing the overall supervision of the trial. These guide-
lines have been used in the development of local terms of
reference by the majority of UK Clinical Trials Units
(CTUs) who, in a recent survey [4], reported having TSC
terms of reference in place. However, many modified the
MRC guidelines from other sources and their own experi-
ences, suggesting that the TSC terms of reference should
be updated.
We aimed to explore the roles and responsibilities of
the TSC from the perspective and experience of an
expert panel of clinicians, trial methodologists and stat-
isticians, and to use this to inform revision of the MRC
TSC terms of reference. This was one of three projects
funded by the MRC Hubs for Trials Methodology Re-
search Network on Trial Steering Committees. One of
these funded projects focused on diagnostic studies,
whilst this project and a separate ethnographic study
focused on TSCs for clinical trials. A member of the
ethnographic study (JAL) acted as an intermediary be-
tween the ethnographic project and the current study.
Methods
The study management group (NH, EC, SL, JN, GM,
MS, JAL, and CG) submitted nominations for expert
panel membership with subsequent voting. Individuals
with two or more votes (n = 10) were invited to join the
panel, seven accepted (DGA, CB, JB, MKC, DE, SE, and
PS) and attended one (n = 4) or both (n = 3) of the
expert panel meetings. Members of the study manage-
ment group also attended and participated in each
meeting. Panel expertise included statisticians, trial meth-
odologists, clinicians, contributors to the DAMOCLES
study and CTU Directors/Deputy Directors. Members of
the expert panel and attending study team had previously
acted as members (independent and non-independent) of
trial oversight committees.
Prior to the first meeting, a list of questions relating to
the role and responsibilities of the TSC was developed.
There were twelve categories of questions, some of which
included additional sub-questions (Table 1). They were
based on the questions used by the DAMOCLES study [5]
and included additional questions developed by the study
team using their personal experience and responses to the
CTU survey [4]. These additional questions related to
interactions between the TSC and the DMC. In particular,
they addressed whether there are issues that the TSC
should not ask the DMC to comment on and also what
the role of the TSC is in situations where there is no
DMC. The increasing call for data sharing, for which the
MRC also has a policy [6], led to the inclusion of a ques-
tion on the role of the TSC in the response to requests for
sharing of data.
Questions were circulated to the expert panel, and
members were asked to independently identify their
five priority questions for discussion at the upcoming
face-to-face meeting. Four questions were prioritised
by at least 70 % of the group (Table 1). Members of
the expert panel were not invited to add additional
questions prior to the meetings but rather were encour-
aged to discuss the questions and to discuss broader issues
should they feel that there were important uncertainties to
address.
Following the first meeting, all agreed that a follow-up
meeting to discuss the remaining questions was warranted
and would allow all questions to be considered.
Before the meeting, a summary of relevant sections
from guidance identified through the CTU survey, a
literature search, and requests made to national and
international funding bodies was provided. Specifically,
these documents were guidance from the DAMOCLES
report [2], MRC Guidelines for Good Clinical Practice
[1], and the TSC requirements from the National Institute
of Health Research (NIHR) Health Technology Assess-
ment (HTA) and Efficacy and Mechanism Evaluation
(EME) funding streams [7] (Additional file 1).
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Each meeting was recorded and transcribed in full. Fol-
lowing the meeting, NH and CG reviewed the transcripts
and categorised the discussions based on the questions in
Table 1; separate categories were generated where other
relevant topics were discussed. Discussions were then
summarised and fed back to the expert panel for com-
ment and agreement. Fully anonymised direct quotes are
presented.
Results
All twelve categories of questions were discussed by
the expert group. Summary results for each question
are described.
What is the role/remit of the TSC? (Question 1)
The role of the TSC includes making decisions, endorsing
TMG actions, and providing advice. The TSC may make
recommendations to the Funder and/or Sponsor of a trial
as well as to the trial team.
‘ …they may make decisions, they may make
endorsements and they may provide advice, so there
are three different things that they would consider
doing and they consider the interests in making those
conclusions, the interests of the trial, the Funder and
the Sponsor, so that they’re looking at it as a complete
package rather than being responsible to any one of
those three things’.
All acknowledged that there were different TSC models
in place both in the UK and internationally and that one
size does not necessarily fit all clinical trials. JAL presented
the preliminary results of an ethnographic study [8] in
which the role of the independent TSC members had been
described as a ‘critical friend’. The expert panel agreed
with this idea, identifying independent TSC members as
experienced, knowledgeable individuals who ask the
bigger questions that the investigators being so close to
the trial may not think through. The role was described as
not only to ask these bigger questions but also to provide
advice and support to facilitate troubleshooting.
The hierarchy of the oversight committees was dis-
cussed. There was agreement that the TSC, being re-
sponsible for decision-making, is the highest level
oversight committee. In contrast to existing guidance,
which described the TSC as supervisory, members of
the expert panel agreed that the term ‘oversight’ was
more appropriate.
There was much debate on the role of the TSC, its
responsibilities, and who the committee ‘worked’ for.
‘…there is that balance of who are they working for, to
protect, and to what aim? … one is to … make
sure,…, that the Funder isn’t wasting its money; the
other one is the Sponsor to make sure that legally the
trial is being conducted to a good standard, but,
ultimately, it’s to make sure that the trial can deliver
high quality, to answer the question, … to make sure
that it’s got some validity’.
Members of the expert group felt that the TSC did
not work for one particular stakeholder of the trial
but rather that they considered the interests of the
trial holistically from the perspective of past, future,
and current trial participants and patients; trialists; the
Funder; and the Sponsor. This was in contrast with the
major public Funders [7], who felt that the independent
TSC members worked on their behalf, and as such, the
Table 1 Key questions about the role of the Trial Steering
Committee (TSC). Topics prioritised for discussion at the
meeting are marked with an asterisk
1)* What is the role/remit of the TSC?
2) The membership of the TSC:
a. What should the membership of the TSC be with respect to
size, members, and the choice of the Chair?
b. Do TSCs always need independent members and, if so, how many?
c. What is the definition of independence?
d. Should Funders be able to reject TSC members?
e. What, if any, are the implications of the same statistician being
involved in production of DMC report (knowledge of unblinded
comparative data) and being on the TSC?
3) What sort of experience and training should TSC members have?
4) What is the role of the TSC prior to trial recruitment?
5)* What material should be available to a TSC (meeting report
contents)?
a. Should a TSC see any data split by treatment groups?
b. Should external evidence be incorporated and how?
c. How does the material differ for TSCs that cover multiple trials?
6) What are the questions that the TSC should not ask the DMC to
make recommendations on, for example, change to primary outcome
or target sample size (other than pre-planned internal pilot)?
7) If there is no DMC, what is impact on the role/remit of the TSC?
8) How should decisions be reached within the TSC?
9)* How should ethical issues be handled in TSCs? For example, what if
higher rates of adverse events were observed in one site or with one
surgeon or an occurrence of a potential serious breach has occurred,
for example, in dosing?
10)* What should be done in difficult/complex situations?
a. What should be done when there is a recommendation from the
DMC to stop the trial, who should be unblended, and what are the
implications if the trial then does not stop?
b. What should be done when decisions are made on site closures
guided by performance?
c. What should be done when Funders stop/withdraw funding?
d. What should be done when an external body wants access to the
data while the trial is on-going, for reasons such as design of a
new trial or interest from industry?
11) What should the TSC’s role be concerning publications? Please
consider publications prior to the main trial report and subsequent
articles.
12) What should the TSC’s role be concerning requests for data sharing?
Please consider requests prior to and following the main publications.
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Funder should have the power to appoint and dismiss
members. In cases where public Funders consider the
TSC to work on their behalf, the expert panel recom-
mended that this responsibility be clearly specified in the
terms of reference and invitations issued to independent
members to join the TSC.
‘…in any terms of references there will have to be
an explicit statement in there if it’s an HTA [Health
Technology Assessment] trial that actually the TSC
is working on behalf of the Funder if that’s the case…
TSC members will have to sign up to that
constraint…’
The panel felt that in commercial studies, it would
make uncomfortable reading if the terms of reference
stated that the TSC worked for the commercial funder.
It is reasonable for the Funder’s interests to be repre-
sented, but the means of achieving this needs consider-
ation. Perhaps, so as not to sway the balance of interests
represented, not all independent TSC members should
work for the Funder. However, this approach assumes
that that the Funder’s interests are different from those
of other stakeholders. This issue needs clarification and
for Funders to explicitly state their ‘interests’. For example,
for a public funding body, interests may, in fact, be more
than solely financial and be heavily weighted towards
participant rights and well-being, scientific integrity, and
contribution to the evidence base.
The membership of the TSC: What should the
membership of the TSC be with respect to size, members,
and the choice of Chair? (Question 2a)
The MRC guidance recommends a minimum TSC mem-
bership of an independent Chair and at least two other
independent members, one or two (non-independent)
principal investigators (meaning the Chief Investigator)
and, where possible, a PPI contributor. The HTA guidance
is more detailed, expecting the TSC to comprise an in-
dependent Chair, one or more independent clinicians,
one or more independent statisticians/epidemiologists/
diagnosticians and at least one PPI contributor, with inde-
pendent members being a 75 % majority [7] (Additional
file 1).
The expert panel agreed that the membership should
include an independent Chair and at least two other
independent members. Whilst including an independent
statistician is recommended, the panel noted that there
is a current paucity of suitably experienced statisticians
in the UK. However, the panel agreed that this should
not be used as an argument against recommending best
practice.
Discussions suggested that a trial methodologist may
be a suitable alternative to a statistician, provided that
the role is clearly specified. Where issues arise during
a trial that require alternative expertise, additional
TSC members should be co-opted to provide advice
and opinion in their field.
‘Also there’s no reason why a [trial] steering
committee has to just be one group who will deal
with all eventualities. There’s no reason why you
couldn’t come to a situation and say, we’re
uncomfortable with this, we need an expert on what
happens when you have X happening, let’s co-opt
someone in’.
However, co-opting may have implications on the length
of time to make a decision on DMC recommendations.
This is particularly important in the example given by a
statistician when the DMC is recommending stopping the
trial.
‘… quite often you don’t particularly need statistical
skills, although it’s very valuable, but where you
absolutely need statistical skills is if … any complex
things come up, like a decision comes up from [the]
DMC saying, I think we need to close the trial. So for
me statistical expertise is essential on the TSC’.
‘ …you’ve got a trial that’s running and the DMC have
made a recommendation to stop on the grounds of
safety, then you’ve got a TSC considering that
recommendation who, say for example, doesn't have a
statistician involved, so they’ve [the TSC] got to go
and find that expert and then we’ve got to get them
informed about the trial, bring them up to speed…,it’s
the impact that that might have on how long the trial
continues for after the DMC has made its
recommendation’.
The choice of Chair is important. Whilst they should
have TSC experience, they do not necessarily need to be
a clinician. As with DMCs, the Chair is sometimes
chosen by the Sponsor or the investigators running the
trial, and sometimes by the TSC themselves. In either
case, the process of choosing the Chair should be clear
and detailed in the invitation to join the TSC.
‘…the TSC Chair should have the experience and
knowledge to be able to delve into those things -
performance of the trial, all the statistics that enable
you to see whether the trial is succeeding, compliance
or adherence, … and direct the committee on what is
needed if there are problems with those data’.
‘[in relation to the TSC Chair] It’s about the skills of
the person rather than this, that or the other
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discipline…so that we can move away from that kind
of expectation that it should be a clinical, and we can
say openly it could either be clinical or non-clinical’.
Do TSCs always need independent members and if so
how many? (Question 2b)
Guidance on the membership of the TSC focuses on the
independent membership, yet TSCs also include non-
independent members, who are generally members of
the TMG. However, the balance of membership should
favour independent members to ensure that when consen-
sus cannot be achieved, and voting is required, decisions
reached are not unduly influenced by the trial team’s
investment in the trial.
Additional trial team members and Sponsor or Funder
representatives may attend the TSC to provide informa-
tion only, but they are not considered members of the
TSC; therefore, when a vote is required to reach a deci-
sion, these members should not be included in voting (see
also question 8: How should decisions be reached within
the TSC?).
No difference should exist between the aims of the
non-independent and independent TSC members. Their
relationship should be viewed as collaborative, with each
member having respect for what the others contribute.
Independent members offer experience, expertise, and
a fresh look at the trial. On the other hand, non-
independent members have an important role in the
provision of in-depth knowledge of the day-to-day run-
ning of the trial. Nevertheless, the TSC should only be
considered quorate for decision-making when the number
of independent members outweighs the number of voting
non-independent members. This approach offers more
flexibility than the current HTA guidelines, which require
the TSC to have a 75 % majority of independent members
and a 67 % attendance of all appointed members to be
quorate for decision-making. However, these recommen-
dations do not take into account the specialities that
should be represented or the appropriate composition and
number of members present for decision-making.
‘If a trial is going to be steered, then the people
who are the helm should have a say in how it’s
steered … because they [the trial management
group] have the most investment in the trial and
they may be more knowledgeable than people on
the [trial] steering committee about that trial, and
I think they do have a stake in it and I feel it’s
wrong to exclude them from the decision-making
process’.
What is the definition of independence? (Question 2c)
Independence was described by the expert panel as ‘not
perceived to be influenced by the trial investigators, the
Funder or the Sponsor’. To ensure that independence is
maintained, the TSC independent members should not
be from the same institution as the Sponsor, co-Sponsor,
co-applicant, or the clinical trials unit involved in the
management of the trial. When there is potential for a
perception of influence, the members should clarify that
it does not prohibit them from making impartial deci-
sions. The expert panel recommended that independent
members ask themselves the question ‘how will this
work if things go wrong?’
Some UK Funders will not accept an independent
TSC member if they are from the same institution as
one of the investigators or recruiting sites. This criterion
is potentially too restrictive, and expert panel members
reported incidences where this definition was difficult to
enforce and agreed that this should be a desirable criter-
ion rather than mandatory. Instead, they proposed that
those responsible for appointing TSC members, often
the Funders, should be reassured of the absence of any
working relationship that would influence the decision-
making of the independent TSC member.
‘I've seen somewhere there's a recognition that
somebody is from the same institution. It’s
declared as an interest but it’s not seen as a
problem so long as it’s upfront that that’s an issue.
Especially if it’s a clinical/non-clinical definition of
difference’.
‘I would prefer an experienced statistician from the
same institution to an inexperienced statistician seen
as more independent’.
Should funders be able to reject TSC members?
(Question 2d)
A consideration of both the appropriateness and inde-
pendence of proposed independent members is required
and for UK publically funded trials, this role is often
taken on by the Funder and may be a condition of fund-
ing. Concerns were expressed that if a Funder has the
right to both appoint and dismiss members, then the
independence of the members from the Funder is
compromised.
‘If you are appointed by the Funder and they have the
right to unappoint you, then you are not really
independent of them…’
The expert panel recommended that the Sponsor, given
their overall responsibility for the trial [9, 10], should also
be ultimately responsible for appointing and dismissing
TSC members, an approach taken for DMC members
within the ICH GCP [11]. However, it is important
for all stakeholders to be confident in the expertise
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and independence of the proposed members. The ex-
pert panel recommended reaching agreement between
stakeholders with provision of clear reasons should a
stakeholder wish to reject or dismiss members.
If concerns are raised about the conduct or participation
of an independent member, then these concerns should
be discussed in the Trial Management Group. The Chief
Investigator, as Chair of the TMG, should then lead on
discussions with the TSC member to give the opportunity
to acknowledge difficulties and act accordingly. If the
concerns are maintained, then the decision to dismiss
ultimately lies with the Sponsor.
What, if any, are the implications of the same statistician
being involved in production of the DMC report (with
knowledge of unblinded comparative data) and being a
member of the TSC? (Question 2e)
In an ideal scenario, where statistical resources are not
limited, the panel agreed that the statisticians involved in
the preparation of a DMC report that contains unblinded
or comparative data should not be a voting member of the
TSC. The key issue discussed was whether the statistician
felt that their knowledge of the data in the DMC report
would compromise their contributions and decision-
making. Many of the expert panel felt that this would not
be the case, provided that the statistician was experienced
and confident to refuse to answer questions that could
lead to inferences about effectiveness or safety between
treatment arms. The panel noted that the knowledge of
the unblinded statistician reflected a specific data cut and,
therefore, a point in time that may no longer reflect the
current situation in the trial.
‘…the statistician…has access to unblinded data but
the result of that unblinded data will probably be
different tomorrow than it is yesterday, so they only
ever hold probably out of date information. So
actually that’s why most statisticians can go through a
whole trial because they’re never dealing with a set
piece of information, it’s only as good as the last
analysis’.
The discussion did not result in a firm answer but
rather that the pros and cons of each circumstance
should be considered; however, the panel agreed that the
statistician producing the DMC report could attend the
TSC meetings as an observer.
‘…it seems that there are considerations for that
[statistician involved in the DMC report attending the
TSC meeting] but I don’t think that it should be
frowned upon or a case made for it, you should just
consider what the pros and cons are for the practice
of the trial’.
What sort of experience, training, or preparation should
TSC members have? (Question 3)
A TSC should represent a mix of skills and include both
statistical/methodological and clinical inputs. All mem-
bers of the TSC should have a commitment to the trial
and skills that will help them act within their role as a
TSC member, including being actively involved in trials
themselves. Training to ensure the future capacity of
experienced members is essential. Prior to acting as an
independent member, the member should exhibit previ-
ous trials experience and acting as a non-independent
member or an as observer for part of a wider trial team
should be required.
‘…..but always try and have a junior person come
and shadow or just observe, because I can remember
when I first went to one of those [a TSC meeting],
I hadn’t a clue what I was supposed to do, and I
actually don’t think anyone else had much of a clue
what they were meant to do either, but we have
moved on a long way. But it is vital, yes there are too
few people with a lot of experience, we need to…
continually build up capacity’.
Members acting in an independent capacity for the
first time may benefit from an independent mentor who
would not attend the TSC meetings but would be bound
by confidentiality and be willing to discuss issues with
the appointed member.
Further discussion took place specifically about the
experience of the independent TSC Chairperson. The
expert panel considered the experience of the Chair to
be particularly important and that the Chair, as in the
DAMOCLES recommendations for DMCs, should have
previous experience of TSC meetings and be able to
facilitate meetings and enable effective interaction within
the group.
‘…you need a range of skills, you need a strong
Chairman who is experienced …, and who has a good
relationship with the trial investigators and is able to
speak to them, often about [difficult] issues…’
What is the role of the TSC prior to trial recruitment?
(Question 4)
The TSC is usually established after notification of a fund-
ing award, with the first meeting of the TSC taking place
between gaining ethical approval and the start of recruit-
ment. Like the DMC, the main role of a TSC prior to trial
recruitment is to agree on the way in which they will oper-
ate and to review the trial protocol. Scheduling a joint first
meeting of the TSC and DMC can be helpful. As indicated
in DAMOCLES, due to the timing of this meeting, this
first meeting usually involves protocol acceptance rather
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than proposing protocol changes. The expert panel con-
sidered the following statement from DAMOCLES to
apply equally to TSCs: ‘All potential DMC members
should have sight of the protocol/outline before agreeing
to join the committee. Before recruitment begins, the trial
will have undergone review by the Funder/Sponsor (for
example, peer review for public sector trials) and scrutiny
by other trial committees and a research ethics committee.
Therefore, if a potential DMC member has major reserva-
tions about the trial (for example, the protocol or the
logistics), he/she should report these to the trial office and
may decide not to accept the invitation to join’.
‘…there's been peer review, there's been Funders’
changes. … And I think we shouldn’t, as a TSC, then
undo that, because in a sense you are going back to
the Funder and saying, well, should you have funded
this?’
Attention should be given to the timing of the next
TSC meeting following protocol acceptance; ideally, this
meeting will be planned based on time elapsed rather
than on patient numbers recruited. This approach to the
timing of the meeting ensures that issues with trial open-
ing, site opening, or recruitment can be addressed. The
TSC should also consider themselves to be on standby
throughout the trial should important issues arise, particu-
larly if there is a planned DMC meeting.
‘I guess maybe you base it on time rather than on
those first few patients coming in, because there may
be something going on that means that recruitment is
very slow, and that you want the TSC to be involved
with’.
All agreed that review and approval of the trial protocol
was essential and that the terms of reference should
include a statement to acknowledge that members have
read and agreed on trial conduct in accordance with a spe-
cified version of the trial protocol. Formal sign off of the
protocol by the TSC, on the other hand, is not required.
What material should be available to a TSC (meeting
report contents)? Should a TSC see any data split by
treatment groups? (Question 5a)
The expert panel debated the roles of the TSC and the
DMC because the potential existed for the line between
these different roles to be blurred with resulting duplica-
tion of effort. Specific reference was given to the checks
of randomisation and review of baseline data split by
treatment group; in this instance, the panel agreed that
whilst the TSC would need to be assured that such
checks had taken place, the actual completion of the
checks was normally the responsibility of the DMC.
‘But you normally have… [DMC] dummy reports…
within which there’s one section which is based on
randomisation and the checks or issues with
randomisation, so you know that the DMC have been
supplied with the information …. So, for me, I think it
sits with the DMC, and the DMC can then make a
recommendation to the TSC who doesn't need to see
that split by treatment group’.
All accepted that the TSC should not view post-
baseline data split by treatment group, but an exception
could be made for baseline data, provided that the justi-
fication was clear and that this was agreed on in advance
by both the DMC and the TSC.
The panel also recommended that the TSC members
are given the opportunity to comment on the proposed
content of the routine DMC reports, prepared at agreed-
upon stages of the trial by the trial statistician and pro-
vided to the DMC, so that the TSC members can be
assured that the DMC is provided with all necessary
information to check areas of concern. Yet, changes
required by the DMC in response to viewing reports
should not be fed back to the TSC in case this alerts the
TSC to areas of concern that should remain confidential
to the DMC.
During the trial, the TSC should be provided with a
report that is based on the information included in the
open section of the DMC report. Care should be taken
to avoid unblinding of any party (TSC or TMG) by
inclusion of data based on the timing of visits or safety
profiles.
The first meeting of the TSC should agree on the
content of TSC reports. The panel reviewed the example
templates for TSC agendas and reports included in the
MRC guidelines for Good Clinical Practice [1]. The
content was agreed on with some minor additions, and a
suggested template is provided in Table 2. A summary of
core documents that the TSC should have opportunity to
comment on, together with reference documents that
should be made available to the TSC, are given in Table 3.
What material should be available to a TSC (meeting
report contents)? Should external evidence be
incorporated and how? (Question 5b) How does this
material differ for TSCs that cover multiple trials?
(Question 5c)
Question 5b and 5c were not discussed in detail by the
expert panel. With respect to external evidence, the panel
agreed that it is the responsibility of the Chief Investigator
(CI) and the trial team to provide information on new
external evidence. There were limited examples of TSCs
that cover multiple trials, and therefore, a case-by-case
approach to the materials available should be taken in
these circumstances, while using the suggested report
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content and documentation (Tables 2 and 3) as a starting
point for discussions.
What are the questions that the TSC should not ask the
DMC to make recommendations on, for example, change
to primary outcome or target sample size (other than
pre-planned internal pilot)? (Question 6)
Discussion on question 6 was limited, and the expert
panel noted that it was difficult to identify examples. The
panel agreed that blinding of the TSC must be maintained,
and that the TSC should not request the DMC to provide
opinion on matters that could be influenced by their
knowledge of comparative analyses. Examples of such
matters include changes to primary outcome [12, 13],
amendments to statistical analysis plans, and planned
sample size.
If there is no DMC, what is the impact on the role/remit
of the TSC? (Question 7)
DAMOCLES describes circumstances where a DMC
might not be required and states that this decision is
made by the TSC, although input may also be needed
from the Funder and Sponsor. The expert group noted
that where there is no DMC, the TSC members should
consider the justification and agree whether this is appro-
priate. Members of the TSC should only agree to member-
ship if they are comfortable with the oversight structure in
place for the trial.
Furthermore, the TSC should remain blinded in in-
stances where there is no DMC, with only pooled data
being reviewed. Where circumstances arise that cause
the TSC concern, they should convene an emergency
DMC. This emergency DMC should include independ-
ent members, who will review the un-blinded data and
make a recommendation to the TSC, however the time-
frame will need to be considered.
How should decisions be reached within the TSC?
(Question 8)
Wherever possible, the TSC should aim to reach consen-
sus with all members (non-independent and independent)
on the preferred plan of action for addressing an issue.
Voting may be necessary when consensus cannot be
reached, but the voting rights of members should be made
clear, and as already described, the number of independent
members voting should outweigh the number of non-
independent members. See question 2b.
How should ethical issues be handled in TSCs? For
example, what if higher rates of adverse events were
observed in one site or with one surgeon or an
occurrence of a potential serious breach, for example,
dosing? (Question 9)
The TSC can have a role in contextualising complex
ethical issues and identifying an appropriate course of
action. The TSC also has a role in identifying early issues
that might represent ethical concerns, such as deviation
from the trial protocol, unexpected events that comprom-
ise patient safety, rights or wellbeing, and the potential
impact of new external information. The panel recom-
mends that when such issues are identified, they should
be fed back to the trial team and a course of action agreed
on in a case-by-case basis. For example, there may be
some instances where further discussion takes place with
the TSC, and a course of action is agreed on; alternatively,
issues may need to be discussed with the trial Sponsor. If
Table 2 Suggested template for Trial Steering Committee (TSC)
meeting agendas and reports
1. Title of trial
2. Funding source(s) and Grant No.
3. Sample size sought
4. Protocol amendments and sub-studies
5. Summary of the data monitoring committee (DMC) recommendations
6. Date recruitment started
7. Proposed date for recruitment end
8. Actual recruitment rate versus target rate (by month/quarter)
9. Acceptance rate as a proportion of the following:
i) those invited to participate, and
ii) if known, all eligible participants
10. Percentage of participants proceeding through each trial stage to
allow monitoring of the recruitment and retention, including
missing outcome data. Not split by treatment/intervention arms.
11. Quarterly/monthly forecasts of recruitment for the planned
remainder of the trial
12. Losses to follow-up as follows:
i) as a proportion of those entered, and
ii) per month/quarter
13. Data management metrics: rate of returns, volume of queries, time
to return, enhanced metrics via electronic data capture
14. Number for whom follow-up has been completed successfully
(or still being successfully followed-up)
15. Overall withdrawal rate and level of withdrawal summarising
those patients who have withdrawn from treatment but are still in
follow-up and those who withdraw with no future contact.
16. Summary of adherence to treatment/intervention. Not split by
treatment/intervention arms.
17. Summary of adverse events including type, for example, adverse
events, serious adverse events and suspected unexpected serious
adverse reactions
18. Completeness of data collected
19. Any available results (pooled)
20. Summary of protocol deviations overall and by site
21. Any organisational problems or other trial issues
22. Issues specific to individual trials (to be specified by the Steering
Committee)
Harman et al. Trials  (2015) 16:597 Page 8 of 14
considered necessary by the TSC or the trial Sponsor,
then issues may also be discussed further with the
Ethics Committee that provided approval for the trial.
An example was given where a trial participant had re-
ceived an incorrect dose of the trial treatment, which
constituted a breach of protocol. Ethical concerns were
raised about whether or not to inform the patient. In this
instance, the TSC were able to identify (taking into
account the views of the PPI contributor) that the dose
received by the participant was not above a standard daily
dose, and that the potential worry that the patient might
undergo, if informed, far outweighed any potential harms.
As a result, agreement was reached by the TSC and the
trial team that the patient did not need to be informed.
What should be done when there is a recommendation
from the DMC to stop the trial, who should be
unblended, and what are the implications if the trial then
does not stop? (Question 10a)
Here the expert panel reflected that in a situation when
the DMC recommends stopping the trial for efficacy
or safety, the TSC should ask the DMC whether their
Table 3 Summary of documentation that should be made available to the Trial Steering Committee (TSC) for approval or
information
Document Documents
that require
TSC approval
Documents that should
be made to be available
to the TSC but do not
require approval
Timing of when document should be approved/made
available
Trial Protocol ✓ Prior to trial opening and then available at all future
trial meetings. Must be agreed on by TSC independent
member as condition of TSC membership, but formal
sign off of the protocol is not required.
Statistical Analysis Plan (if an independent statistician
is a member of the TSC then consider an independent
blind review of the statistical analysis plan)
✓ Approved prior to implementation and then made
available on request at future meetings.
Sub-study proposals/protocols ✓ To be approved prior to submission for regulatory and
REC approval if possible.
TSC terms of reference ✓ Prior to or at the first TSC meeting.
Protocol amendments –major/substantial
amendment
✓ Prior to submission of the amendment to the
Research Ethics Committee.
Protocol amendments –minor/non-substantial
amendment
✓ Throughout the trial, as they arise or as part of the
next scheduled meeting.
Trial publicity/promotion plan ✓ As a minimum, at the next TSC meeting following
document approval by the TMG.
Data sharing agreement if in place ✓ As a minimum, at the next TSC meeting following
document approval by the TMG.
Monitoring plan – to include information of the
monitoring of data quality
✓ As a minimum, at the next TSC meeting following
document approval by the TMG.
DMC report plan ✓ As a minimum, at the next TSC meeting following
document approval by the TMG.
Open DMC report ✓ As a minimum, at the next TSC meeting following the
DMC at which the report was presented or as agreed
with the TSC if meeting frequency means that there
will be as substantial delay in the TSC receiving this
information.
Risk Assessment ✓ As a minimum, at the next TSC meeting following
document approval by the TMG.
Publication policy ✓ As a minimum, at the next TSC meeting following
document approval by the TMG.
Main trial publications ✓ Prior to submission
Participant information sheet and consent form
(important for TSC to review consent form and
what participants are providing consent for)
✓ As a minimum, at the next TSC meeting following
document approval by the TMG.
CRFs/questionnaires/data collection tools ✓ As a minimum, at the next TSC meeting following
document approval by the TMG.
DMC charter ✓ As a minimum, at the next TSC meeting following
document approval by the DMC.
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decision was unanimous and request that the independent
TSC members be unblinded. Should the trial continue,
the unblinded TSC members do not need to be replaced,
but details of who has been unblinded should be included
in the meeting minutes.
‘And do you think that that should happen?
Because if people had a situation where the DMC
said stop, and the independent members of the
[Trial] Steering Committee said, ‘No, no, no,
because you haven’t thought about the late benefit,
look at this, let’s keep it going’, they’re all
unblinded now, what do you do? Do you replace
them even though they’re wise…?’
‘No, let them carry on.’
‘No, I think you just live with it.’
As noted previously, the TSC should be on standby at
the time of a DMC meeting, so that if an issue arises, a
meeting can be scheduled at short notice. The DMC
Chair should communicate any urgent recommenda-
tions to either the Chief Investigator or TSC Chair who
should then convene an urgent meeting to discuss the
recommendations.
The DAMOCLES study [2] identified the need for plan-
ning how disagreements between the DMC and TSC
should be managed, and this was also considered by the
expert panel. All agreed that the process should include
an escalation clause to describe how a difference of
opinion on, for example, changes to the protocol or
trial continuation should be managed. Options could
include referral to the Sponsor, Funder or co-opted
experts. The process should be clarified and agreed
on by all members within the terms of reference.
What should be done when decisions are made on site
closures guided by performance? (Question 10b)
The TSC has a role in reviewing difficulties that arise
in the course of the trial and providing feedback and
guidance to the trial team on what corrective/preventative
actions are necessary and how to implement them.
‘…the TSC, if they are made aware of problem sites,
have a duty to do something about it’.
The TSC should consider patient safety and data integ-
rity and be mindful of the relationships between the trial
site and investigators when making recommendations of
how to progress.
‘Yes. I mean it’s certainly not a key consideration but
some trials are obviously run in very small
communities and it can be really embarrassing for a
Chief Investigator to close a centre’.
In such situations, the TSC can support the CI by
relaying to the centre that the decision was that of
the TSC.
What should be done when Funders stop/withdraw
funding? (Question 10c)
Although the Funder may withdraw funding from a trial,
this does not necessarily mean that the trial should stop,
as the decision to stop the trial ultimately lies with the
Sponsor. In the event that funding is withdrawn, the TSC
should consider whether they agree with trial closure, and
if not, may offer advice and guidance to the trial team on
continuation and alternative sources of funding.
What should be done when an external body wants
access to the data while the trial is on-going, for reasons
such as the design of a new trial or interest from
industry? (Question 10d)
The expert panel noted that the response to this question
would depend on the specific request and the stage of the
trial. As a result, specific guidance could not be generated,
but instead, the panel suggested a general process whereby
requests from Funders or external bodies for information
should be sent to the Chair of the TSC. The TSC should
then discuss the request and determine its appropriateness
for the DMC.
‘Well surely it’s for the TSC to decide just… to
consider requests for data and then to make
judgements based on rational arguments,…it would
be for each TSC to have a discussion about whether
to provide data. And if the trial’s ongoing, …I think
the assumption would be that you wouldn’t provide
data, quite frankly, unless it’s really important…’
What should the TSCs role be concerning publications?
Please consider publications prior to the main trial report
and subsequent articles. (Question 11)
Again, in line with DAMOCLES, [5] all agreed that being
a named author on a trial publication does contravene the
independence of the independent TSC members. How-
ever, the TSC should have the opportunity to comment on
trial publications, and certainly, at a minimum, on the
main trial report. The TSC membership, name and affili-
ation, should be included in the acknowledgements sec-
tion of publications with the permission of the members.
The DAMOCLES study [5] also noted that some had
suggested that the DMC should be responsible for ensur-
ing that reporting occurs. The importance of ensuring
timely reporting was echoed in the expert panel discus-
sions who felt that the TSC had an ethical obligation to
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ensure that trial results were published. Examples were
given where the TSC had helped to push publication by
the trial team and also an example where the trial data
was taken on by the DMC and subsequently reported with
the Chair of the DMC as first author. All agreed these
approaches were acceptable if, without them, the trial
would remain unpublished. The feasibility of an oversight
committee taking on the responsibility of publishing the
results of the trial, if the team fail to do so, needs further
consideration.
What should the TSC’s role be concerning requests for
data sharing? Please consider requests prior to and
following the main publications. (Question 12)
The TSC has a role in reviewing requests for data shar-
ing, particularly when requests, in line with the trial data
sharing agreement, compete with the ongoing or planned
work of the TMG. The TSC may not have a role in all re-
quests for data sharing, only those that require careful
consideration due to implications for ongoing data collec-
tion and planned analyses.
The expert panel remarked that the life span of the
TSC should be taken into account when planning for fu-
ture data requests. These are often submitted sometime
after the trial has ended. A decision should be made as
to whether the TSC would reconvene for such decisions
or would be happy to pass this onto a central committee
considering such requests across a portfolio of clinical
trials, for example, within a clinical trials unit.
Other uncertainties identified from discussions
Expert panel discussion identified further areas of uncer-
tainty in the role and operation of the TSC. These are
discussed below.
Lifespan of the TSC
The lifespan of the TSC was considered not only import-
ant for data-sharing considerations, as already discussed,
but was also felt to need consideration when the TSC is in
place for a feasibility trial that then progresses through to
a pilot and/or main trial. In particular, they addressed
whether the TSC is considered to maintain independence
and continue to act as the TSC for the trial.
‘I think the example [NAME] has where somebody
has been involved already, and was seen as
independent at the start, I think that having a fixed
rule that denotes you can’t continue is a mistake’
An example was also discussed on the role of the TSC
when there is long-term follow-up post-intervention and
the role of the DMC has concluded. All agreed that in these
circumstances the oversight needs of the trial should be
discussed and agreed on as part of the terms of reference.
Sponsorship
Legally, the Sponsor has the ultimate responsibility for a
trial, and legal responsibility remains even when roles
are delegated. However, discussions reflected uncertainty
in the ability of some institutions to fulfil this role fully
due to lack of expertise. In current practice, the Sponsor
often delegates the decision of trial continuation to the
TSC. All agreed that the Sponsor should formally docu-
ment the responsibilities delegated to the TSC. Where
decisions around continuation are not delegated to the
TSC, the recommendations from the TSC should be sub-
mitted to the trial Sponsor.
Indemnity
The TSC is delegated responsibilities by the Sponsor, but
it is often unclear whether the Sponsor also provides
indemnity for the TSC members. The expert panel noted
that professional indemnity for TSC membership may
not be provided by their own academic or clinical institu-
tion, and that for public contributors or retired academics
and clinicians, the situation was even less clear. No rec-
ommendations were made as to who should provide
indemnity, but instead, the panel suggested that indemnity
arrangements should be made clear in the TSC terms of
reference.
Administration
More practical arrangements of the TSC were debated
by the expert panel, and we have included recommended
best practice in the administration of the TSC meetings.
Where a TSC is convened for a single trial, meetings of
the TSC should aim to be scheduled to take place 1 or
2 weeks after the DMC meeting. Where this is not pos-
sible, the Chair of both the TSC and the DMC should be
informed, so that a joint decision on appropriate timing
of meetings can be reached. The frequency of TSC meet-
ing should be determined based on the trial risk assess-
ment. An inexperienced TSC may prefer to meet more
frequently, but this may have implications for the cost of
the trial, including for resources, for organising the meet-
ings, and for preparing the TSC reports. The expert panel
suggested that the terms of reference include a recom-
mended frequency of TSC meetings and the level of
reporting required. Table 2 describes the content of the
TSC reports and agendas. However, shorter, more focused
reports may be appropriate for some meetings and would
make best use of trial resources.
The Chair may choose to take the minutes of meetings,
to delegate this to another independent member or to a
member of the trial team, for example, the trial coordin-
ator or trial administrator. Where the responsibility of
writing minutes has been delegated, they should be
reviewed by the Chair prior to circulation for approval by
all present. The meeting agenda should be based on the
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TSC report; other items may be suggested by the trial
team and agreed on with the TSC Chair. The timelines for
sending documents or reports prior to the meeting should
be agreed on in advance with the TSC members. The TSC
may also convene as independent members only, particu-
larly if there are sensitive issues to discuss, for example,
the conduct of the TMG.
Discussion
Some guidelines for the TSC terms of reference exist,
but the panel felt that these are not exhaustive and may
not consider some important issues in TSC conduct and
membership. One of the key discussion points was the
nature of independence and to whom the TSC was re-
sponsible; in particular, the panel addressed whether the
latter influenced independence. A consistent and trans-
parent approach to the appointment of the independent
TSC members is needed. IFor many trials in the UK,
the Funder is currently responsible for appointing and
dismissing independent members, so input from these
Funders will be crucial in defining for whom the TSC
works, together with the criteria that should be applied
when scrutinising suggested members. Interestingly some
academic journals require the role of the Funder to be
clearly specified in the trial manuscript, yet for many trials
funded by the NIHR HTA programme, this is overlooked
in funding statements [14–20].
We have identified areas where uncertainly remains and
for which additional resources are required. Discourse for
questions 10a-10c (what should be done in difficult or
complex situations) was largely hypothetical due to the
small number of examples available. This corresponds to
the small number of papers identified in DAMOCLES as
reporting what should be done in difficult situations in the
context of the DMC [5]. The expert panel acknowledged
that this gap could be addressed if there was a resource
that allowed experiences to be shared. If members of TSCs
and DMCs could submit examples, this would, over time,
build a repository of issues and potential solutions relating
to DMC and TSC roles independently and the interaction
between the two committees. This could also help to
identify additional examples of questions that the TSC
should not ask the DMC to make recommendations on
(question 6). The way in which the TSC and DMC inter-
act, as described in the MRC guidelines, is well accepted,
but this does not address situations where there is
disagreement between the DMC and the TSC. Further
work is needed to clarify the process to be followed and
the wording of the escalation clause, which is included in
the terms of reference, in these situations. The suggested
repository may benefit from a widened scope to include
anonymised examples of TSC/DMC disagreement and
how they have been handled.
The current lack of training for independent members
was highlighted. Requirements of independence mean
that prior working relationships may exclude a number
of potential independent members, thereby allowing few
alternatives for experienced members if the field is small,
as is the case for independent statisticians and/or trial
methodologists. Capacity building will be essential to
ensure a suitable pool of experts who have had the
necessary training and experience to contribute to a TSC
as an independent member; these experts must under-
stand the workload, commitment and potential academic
benefits of membership, for example, gaining knowledge
from shared experience. Capacity building for statisticians
will be addressed somewhat by an ongoing national initia-
tive to create a database of statisticians (Search for Over-
sight Statisticians [21]). However, further thought on how
best to build capacity for other disciplines is required. The
model of TSC oversight on which recommendations have
been made is that of a TSC acting for a single trial. How-
ever, results from the CTU survey [22] show that one
quarter of UK Clinical Trials Units use at least one
umbrella TSC, which has oversight of a number of trials
that are taking place in the same clinical condition. Only
one member of the expert panel had experience of such a
model, so debate about the pros/cons and specific terms
of reference consideration in these circumstances were
limited. The resulting recommendation is that the content
of the TSC reports and agendas should be considered
on a case-by-case basis. However, further exploration
of current practice with those CTU survey responders
who use umbrella TSCs may help to distinguish spe-
cific considerations for this model of oversight.
Public representation on a TSC is recommended by
both MRC and some UK Funder guidelines, but the
absence of an expert panel discussion and published
literature on the role of an independent PPI contributor
was notable. Buck et al. reviewed planned PPI activities in
NIHR HTA funded trials. When a PPI contributor was a
member of the TSC, his/her role was unclear to all
involved, including the PPI contributors themselves [23].
The preferred role of PPI contributors was in managerial
or responsive roles, and these roles were also found to be
more likely to achieve impact compared to involvement in
oversight roles including the TSC [24]. In addition, a
survey of UK CTUs demonstrated that identification of an
appropriate PPI contributor was challenging [22]. The
role, expected contributions, and need for independence
of public contributors in the oversight of clinical trials
warrant further investigation.
Conclusion
Discussion among members of the expert panel and the
study team has provided valuable information, based on
real-life experience, and the recommendations made will
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contribute to the re-development and expansion of the
MRC guidelines [1]. Some uncertainties could not be
resolved in the expert panel meetings; one uncertainty,
in particular, was the identification of examples of com-
plex ethical issues and the training requirements of inde-
pendent members. These, together with the role of public
contributors as independent TSC members, merit further
consideration. Experiences shared at the expert panel
meetings were those of involvement in UK publically
funded trials. Whilst many of the issues discussed are
relevant beyond this scope, the transferability of rec-
ommendations will be dependent on commercial and
international oversight requirements for randomised
controlled trials.
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